Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Aug 1;210(3):367-368.
doi: 10.1164/rccm.202402-0337LE.

Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good

Susanne Stowasser  1 , Gregory P Cosgrove  2 , Eric S White  3
Affiliations
Comment

Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good

Susanne Stowasser et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Raghu G, Ghazipura M, Fleming TR, Aronson KI, Behr J, Brown KK, et al. Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on ‘feels, functions, survives’. Report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the National Institutes of Health, a patient advocacy organization, and a regulatory agency. Am J Respir Crit Care Med . 2024;209:647–669. - PubMed
    1. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib. N Engl J Med . 2015;372:1189–1191. - PubMed
    1. Maher TM, van der Aar EM, Van de Steen O, Allamassey L, Desrivot J, Dupont S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med . 2018;6:627–635. - PubMed
    1. Lancaster LH, Cottin V, Ramaswamy M, Goldin JG, Kim GJ, et al. PLN-74809 shows favorable safety and tolerability and indicates antifibrotic activity in a phase 2a study for the treatment of idiopathic pulmonary fibrosis [abstract] Am J Respir Crit Care Med . 2023;207:A2777.
    1. Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, et al. 1305-0013 Trial Investigators Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med . 2022;386:2178–2187. - PubMed

LinkOut - more resources